Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Keating

Showing results (51-60 of 341) with videos related to

Pageof 35
Sort By:
Cancer Chemotherapy and Pharmacology|November 12, 2003
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivityElizabeth Oldham Hileman, Jinsong Liu, Maher Albitar, et al.
Leukemia & Lymphoma|June 7, 2006
Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot studyApostolia-Maria Tsimberidou, Michael J Keating, Carlos E Bueso-Ramos, et al.
Blood|December 25, 2014
Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cellsViralkumar Patel, Kumudha Balakrishnan, Michael J Keating, et al.
Cancer|January 20, 2011
Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Susan O'Brien, et al.
Blood|January 18, 2003
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agentsYan Zhou, Elizabeth O Hileman, William Plunkett, et al.
Leukemia & Lymphoma|December 9, 2015
Metabolism pathways in chronic lymphocytic leukemiaUri Rozovski, Inbal Hazan-Halevy, Merav Barzilai, et al.
Leukemia Research|May 25, 2007
Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosisPatricia Ault, Alice Lynn, Constantine S Tam, et al.
Cancer|March 13, 2010
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrenceStefan Faderl, Alessandra Ferrajoli, William Wierda, et al.
Leukemia & Lymphoma|June 20, 2015
Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cellsFabiola Cervantes-Gomez, Bethany Lavergne, Michael J Keating, et al.
Leukemia Research|August 4, 2009
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 YearsStefan Faderl, William Wierda, Susan O'Brien, et al.
Pageof 35

Showing results (51-60 of 341) with videos related to

Sort By:
Pageof 35
Cancer Chemotherapy and Pharmacology|November 12, 2003
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivityElizabeth Oldham Hileman, Jinsong Liu, Maher Albitar, et al.
Leukemia & Lymphoma|June 7, 2006
Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot studyApostolia-Maria Tsimberidou, Michael J Keating, Carlos E Bueso-Ramos, et al.
Blood|December 25, 2014
Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cellsViralkumar Patel, Kumudha Balakrishnan, Michael J Keating, et al.
Cancer|January 20, 2011
Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Susan O'Brien, et al.
Blood|January 18, 2003
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agentsYan Zhou, Elizabeth O Hileman, William Plunkett, et al.
Leukemia & Lymphoma|December 9, 2015
Metabolism pathways in chronic lymphocytic leukemiaUri Rozovski, Inbal Hazan-Halevy, Merav Barzilai, et al.
Leukemia Research|May 25, 2007
Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosisPatricia Ault, Alice Lynn, Constantine S Tam, et al.
Cancer|March 13, 2010
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrenceStefan Faderl, Alessandra Ferrajoli, William Wierda, et al.
Leukemia & Lymphoma|June 20, 2015
Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cellsFabiola Cervantes-Gomez, Bethany Lavergne, Michael J Keating, et al.
Leukemia Research|August 4, 2009
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 YearsStefan Faderl, William Wierda, Susan O'Brien, et al.
Pageof 35